| Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization WW O'Neill, P Serruys, M Knudtson, GA van Es, GC Timmis, ... New England Journal of Medicine 342 (18), 1316-1324, 2000 | 251 | 2000 |
| Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial SS Anand, J Bosch, JW Eikelboom, SJ Connolly, R Diaz, P Widimsky, ... The Lancet 391 (10117), 219-229, 2018 | 238 | 2018 |
| Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial SJ Connolly, JW Eikelboom, J Bosch, G Dagenais, L Dyal, F Lanas, ... The Lancet 391 (10117), 205-218, 2018 | 112 | 2018 |
| Heparin‐induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases MC Kappers‐Klunne, DMS Boon, WCJ Hop, JJ Michiels, J Stibbe, ... British journal of haematology 96 (3), 442-446, 1997 | 111 | 1997 |
| The challenge of acute coronary syndromes ML Simoons, E Boersma, C van der Zwaan, JW Deckers The Lancet 353, s1-s4, 1999 | 41 | 1999 |
| for the EXCITE Trial Investigators: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization WW O’Neill, P Serruys, M Knudtson, GA Van Es, GC Timmis, ... N Engl J Med 342, 1316-1324, 2000 | 10 | 2000 |
| Troponin-I identifies patients with unstable coronary artery disease who benefit from long-term oral glycoprotein IIb/IIIa inhibition: The FROST study M Akkerhuis, C van der Zwaan, RG Wilcox, KL Neuhaus, A Vahanian, ... Circulation 100 (18), 292-292, 1999 | 10 | 1999 |
| Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective … KM Akkerhuis, M Van den Brand, C van der Zwaan, HOJ Peels, ... Heart 85 (4), 444-450, 2001 | 8 | 2001 |
| Design and objectives of the evaluation of oral xemilofiban in controlling thrombotic events (EXCITE) study WW O'NEILL, P SERRUYS, M KNUDTSON, GANN VAN ES, GC TIMMIS, ... Journal of Interventional Cardiology 12 (2), 109-116, 1999 | 8 | 1999 |
| Early coronary patency evaluation of a platelet glycoprotein receptor antagonist (abciximab) in primary PTCA LFM Merkhof-Van Den, A Liem, F Zijlstra, H Olsson, H Nilsson, L Grip, ... Circulation 96 (8S), 1997 | 7 | 1997 |
| Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo … DL Bhatt, PG Steg, SR Mehta, LA Leiter, T Simon, K Fox, C Held, ... The Lancet 394 (10204), 1169-1180, 2019 | 4 | 2019 |
